BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12954070)

  • 1. Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: an extremely powerful analgesic.
    Schütz J; Spetea M; Koch M; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2003 Sep; 46(19):4182-7. PubMed ID: 12954070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
    Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
    Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
    Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
    Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
    J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
    Grundt P; Jales AR; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2003 Apr; 46(8):1563-6. PubMed ID: 12672258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration.
    Nagase H; Nemoto T; Matsubara A; Saito M; Yamamoto N; Osa Y; Hirayama S; Nakajima M; Nakao K; Mochizuki H; Fujii H
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6302-5. PubMed ID: 20850307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug design and synthesis of epsilon opioid receptor agonist: 17-(cyclopropylmethyl)-4,5alpha-epoxy-3,6beta-dihydroxy-6,14-endoethenomorphinan-7alpha-(N-methyl-N-phenethyl)carboxamide (TAN-821) inducing antinociception mediated by putative epsilon opioid receptor.
    Fujii H; Narita M; Mizoguchi H; Murachi M; Tanaka T; Kawai K; Tseng LF; Nagase H
    Bioorg Med Chem; 2004 Aug; 12(15):4133-45. PubMed ID: 15246090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
    Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
    J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR study of opioid receptor ligands: mono- and bis-indolomorphinans.
    Li F; Yin C; Chen J; Liu J; Xie X; Zhang A
    Chem Biol Drug Des; 2009 Oct; 74(4):335-42. PubMed ID: 19691470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.
    Spetea M; Windisch P; Guo Y; Bileviciute-Ljungar I; Schütz J; Asim MF; Berzetei-Gurske IP; Riba P; Kiraly K; Fürst S; Al-Khrasani M; Schmidhammer H
    J Med Chem; 2011 Feb; 54(4):980-8. PubMed ID: 21235243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
    Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
    Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
    Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
    J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
    Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
    Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.